160 related articles for article (PubMed ID: 20850924)
1. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Jin L; Tabe Y; Kojima K; Zhou Y; Pittaluga S; Konopleva M; Miida T; Raffeld M
Cancer Lett; 2010 Dec; 299(2):161-70. PubMed ID: 20850924
[TBL] [Abstract][Full Text] [Related]
2. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Tabe Y; Sebasigari D; Jin L; Rudelius M; Davies-Hill T; Miyake K; Miida T; Pittaluga S; Raffeld M
Clin Cancer Res; 2009 Feb; 15(3):933-42. PubMed ID: 19188164
[TBL] [Abstract][Full Text] [Related]
3. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
4. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
8. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
9. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
10. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
14. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor gene 1 enhances nutlin-3-induced apoptosis.
Lee SY; Choe YJ; Park JY; Lee SS; Kim YH; Shin SJ; Chung YJ; Kim HS
Oncol Rep; 2014 Jan; 31(1):131-6. PubMed ID: 24190574
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Ri M; Iida S; Ishida T; Ito A; Yano H; Inagaki A; Ding J; Kusumoto S; Komatsu H; Utsunomiya A; Ueda R
Cancer Sci; 2009 Feb; 100(2):341-8. PubMed ID: 19068089
[TBL] [Abstract][Full Text] [Related]
17. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
18. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
19. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA
PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382
[TBL] [Abstract][Full Text] [Related]
20. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]